The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis

Jinyun Xu; Jiaowei Gu; Yan Zhao; Huihua Meng; Li’an Du; Ruibo Zhang; Hao Jiang; Jianming Luo

doi:10.18632/oncotarget.21154

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis

Jinyun Xu, Jiaowei Gu, Yan Zhao, Huihua Meng, Li’an Du, Ruibo Zhang, Hao Jiang and Jianming Luo _

PDF | HTML | How to cite

Oncotarget. 2017; 8:99041-99048. https://doi.org/10.18632/oncotarget.21154

Metrics: PDF 1501 views | HTML 3235 views | ?

Abstract

Jinyun Xu1,2, Jiaowei Gu2, Yan Zhao2, Huihua Meng1, Li’an Du1, Ruibo Zhang2, Hao Jiang2 and Jianming Luo1

1Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

2Department of Pediatrics, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China

Correspondence to:

Jianming Luo, email: [email protected]

Keywords: BIM, chronic myeloid leukemia, tyrosine kinase inhibitor, genetic polymorphism, drug resistance

Received: August 01, 2017 Accepted: September 04, 2017 Published: September 22, 2017

ABSTRACT

A common deletion polymorphism of the gene Bcl-2 like protein 11 (BCL2L11, BIM) has been reported to cause tyrosine kinase inhibitors (TKIs) resistance in several malignant tumors. However, the conclusions were not consistent in chronic myeloid leukemia (CML) individuals. In order to obtain a reliable conclusion, we systematically searched PubMed, Embase, Web of Science, Chinese Biomedical Database, and China National Knowledge Infrastructure and performed the meta-analysis. Six published articles contain 760 East Asian patients were identified from these electronic databases. The methodological quality of one included trial was high, and the others were moderate. Meta-analysis showed that the rate of TKI resistance between the BIM deletion and wild-type group were no statistical significance (OR = 1.24, 95% CI 0.79–1.95). In conclusion, BIM deletion may not a predictor of TKI resistance in CML individuals in East Asia.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21154

Publication Alerts

Meta-Analysis:

The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis

Abstract